Tiny Lung-Artery sensor could help heart failure patients live longer

NCT ID NCT06306573

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study follows 2,500 people with moderate heart failure (NYHA Class II or III) who already have a CardioMEMS sensor implanted in their lung artery. The sensor wirelessly sends pressure readings to doctors, who use the data to adjust medications. Researchers will track survival over two years to see if using this real-time information helps patients live longer compared to a historical benchmark. The goal is to confirm the device's long-term safety and real-world effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CardioMEMS HF System (implantable wireless pressure sensor)
What this could lead to
If successful, this study could confirm that using real-time pressure data from inside the lung artery helps people with heart failure live longer and avoid hospital stays.
What could go wrong
This is an observational follow-up study, not a controlled trial, so it cannot prove cause and effect. The device itself carries risks like infection or sensor failure, and results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abbott Medical

    Atlanta, Georgia, 30313, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.